Stockscreener 앱 받기
0.0325
0.30%
-0.000099
시간 외 거래:
.03
-0.0025
-7.69%
전일 마감가:
$0.0326
열려 있는:
$0.038
하루 거래량:
33,698
Relative Volume:
0.52
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+18.18%
1개월 성능:
+915.62%
6개월 성능:
+160.00%
1년 성능:
+1.88%
1일 변동 폭
$0.0231
$0.038
1주일 범위
$0.0159
$0.04
52주 변동 폭
$0.0009
$0.0698
Nls Pharmaceutics Ag Stock (NLSPW) Company Profile
명칭
Nls Pharmaceutics Ag
전화
41 44 512 21 50
주소
The Circle 6, Zurich
NLSPW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NLSPW
Nls Pharmaceutics Ag
|
0.0325 | 0 | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Nls Pharmaceutics Ag 주식(NLSPW)의 최신 뉴스
Short Interest in NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Decreases By 56.6% - Defense World
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
NLS Pharmaceutics to present Mazindol study at ASCP Meeting - Investing.com Australia
NLS Pharmaceutics to present Mazindol study at ASCP Meeting By Investing.com - Investing.com India
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting - Seeking Alpha
NLS Pharmaceutics (NASDAQ:NLSP) Trading Down 0.6% – Should You Sell? - Defense World
Narcolepsy Therapeutics Market Expected to Reach USD 7,852.93 Million by 2034, Growing at a CAGR of 7.5% As... - WhaTech
Narcolepsy Market: Epidemiology, Therapies, Companies, - openPR.com
Pre-market Movers: STSS, THRD, PTN, VRAX... - RTTNews
Press Release Distribution & PR Platform - ACCESS Newswire
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - ACCESS Newswire
NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine
NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder - marketscreener.com
NLS Pharmaceutics Reports Positive Results in Fentanyl Study - TipRanks
Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models - MarketScreener
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models - marketscreener.com
Kadimastem Ltd. announced that it expects to receive ILS 2 million in funding. - marketscreener.com
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest - ACCESS Newswire
NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire
NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com
NLS Pharmaceutics secures $2M for Kadimastem merger By Investing.com - Investing.com Canada
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider.com
NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa
NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India
NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World
NLS Pharmaceutics announces merger with Kadimastem - Investing.com India
NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com UK
NLS Pharmaceutics CEO Issues Letter to Shareholders - Yahoo Finance
Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com
NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa
NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com India
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - accessnewswire.com
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire
AEX-2 increases total wake duration in mouse model - BioWorld Online
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire
NLS Pharmaceutics reports progress in narcolepsy treatment By Investing.com - Investing.com South Africa
NLS Pharmaceutics reports progress in narcolepsy treatment - Investing.com
Pre-IND meeting guides path forward for ITOL-102 for type 1 diabetes - BioWorld Online
NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - Yahoo Finance
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder - ACCESS Newswire
NLS Pharmaceutics And Kadimastem Unveil Multi-Target Diabetes Approach - Nasdaq
Is NLSP’s price to cash per share ratio a concern for investors? - US Post News
NLS Pharmaceutics (NLSP) Shares Surge As Market Reacts To Potential Merger - Stocks Telegraph
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - Marketscreener.com
NLS and Kadimastem to merge, aim for diabetes care innovation - Investing.com
Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews
Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews
Nls Pharmaceutics Ag (NLSPW) 재무 분석
Nls Pharmaceutics Ag (NLSPW)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.00%
0.54%
자본화:
|
볼륨(24시간):